C. Hayes

发表

Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A.

M. Imamura, N. Hiraga, K. Chayama, 2015, Journal of hepatology.

IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

Yusuke Nakamura, M. Kubo, M. Imamura, 2011, Journal of hepatology.

Impact of viral amino acid substitutions and host interleukin‐28b polymorphism on replication and susceptibility to interferon of hepatitis C virus

Yusuke Nakamura, M. Imamura, N. Hiraga, 2011, Hepatology.

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.

Yusuke Nakamura, K. Chayama, Y. Karino, 2011, The Journal of infectious diseases.

Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state

Yusuke Nakamura, M. Kubo, M. Imamura, 2011, Journal of medical virology.

Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy

M. Imamura, N. Hiraga, K. Chayama, 2010, Antiviral therapy.

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

Yusuke Nakamura, M. Kubo, M. Imamura, 2010, Journal of hepatology.

Management of HCV patients in cases of direct-acting antiviral failure

M. Imamura, K. Chayama, C. Hayes, 2019, Expert review of gastroenterology & hepatology.

The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir

M. Imamura, K. Chayama, C. Hayes, 2017, Expert review of gastroenterology & hepatology.

Hepatitis C virus treatment update — A new era of all‐oral HCV treatment

M. Imamura, K. Chayama, C. Hayes, 2016 .

Ribavirin dose reduction during telaprevir/ribavirin/peg‐interferon therapy overcomes the effect of the ITPA gene polymorphism

N. Hiraga, D. Miki, H. Ochi, 2015, Journal of viral hepatitis.

HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy

K. Chayama, C. Hayes, C. N. Hayes, 2015, Viruses.

Emerging treatments for chronic hepatitis C.

K. Chayama, C. Hayes, C. N. Hayes, 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study

Yusuke Nakamura, T. Tsunoda, M. Kubo, 2013, PloS one.

Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines

K. Chayama, Y. Kawakami, W. Ohishi, 2012, Journal of Gastroenterology.

Emerging Antivirals in the Future

M. Imamura, K. Chayama, C. Hayes, 2017 .

MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma

K. Chayama, C. Hayes, C. N. Hayes, 2016, International journal of molecular sciences.

Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients

M. Imamura, N. Hiraga, K. Chayama, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Risk factors for histological progression of nonalcoholic steatohepatitis analyzed from repeated biopsy cases.

M. Imamura, K. Chayama, D. Miki, 2020, Journal of gastroenterology and hepatology.

Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction

M. Imamura, K. Chayama, D. Miki, 2017, Journal of medical virology.

Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease

M. Imamura, K. Chayama, T. Kawaguchi, 2021, Journal of Gastroenterology and Hepatology.

Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease

M. Imamura, N. Hiraga, K. Chayama, 2018, Journal of Gastroenterology.